NuVasive reported preliminary full year financial results for 2016, with revenue hitting $956 million.
Here are five things to know from the report:
1. The company's full year revenue grew 17.6 percent year-over-year. NuVasive expects 2017 revenue to hit $1.065 billion and to boast a non-GAAP operating profit margin expansion of around 100 basis points compared to 2016.
2. NuVasive's pro forma revenue including acquisitions in the company's financial results is expected to grow 8.7 percent on a constant currency basis.
3. Fourth quarter revenue is expected to reach $265 million.
4. The projected revenue for 2017 includes $10 million in year-over-year currency headwinds. The company is expecting 11.4 percent year-over-year growth.
5. Chairman and CEO Gregory T. Lucier reported the company had stronger than expected preliminary results for 2016. "We remain committed to our longer-term financial performance goals and strategic initiatives that are expected to drive the company's revenue growth and operating margin expansion targets, while continuing to transform healthcare with game-changing technologies," he said.